Results of Mesoblast’s (NASDAQ:MESO; ASX:MSB) Phase 2 trial of its allogeneic mesenchymal precursor cell (MPC) product candidate, MPC-300-IV, in patients with diabetic kidney disease have been published in the current issue of the peer-reviewed journal, EBioMedicine.
The paper concluded that a single intravenous infusion of MPC-300-IV was well tolerated and had positive effects on renal function at the 12-week primary endpoint in the trial with adult patients with Type 2 diabetic nephropathy.
Dr. David Packham, lead author on the publication, said that the efficacy signal observed with respect to preservation or improvement in glomerular filtration rate is exciting, especially given that the trial was not powered to show statistical significance.
Patients receiving a single infusion of MPC-300-IV showed no evidence of developing an immune response to the administered cells, suggesting that repeat administration is feasible and may in the longer term be able to halt or even reverse progressive chronic kidney disease, he added.
